Vaginal estrogen’s safety profile is distinct from systemic hormone therapy, and the evidence behind it goes well beyond comfort. Here is what it covers, and why every woman moving through the menopause transition deserves to know it exists, whether she needs it yet or not.
Vaginal dryness, irritation, and pain during sex are often filed under things women are told to simply live with. They are symptoms of genitourinary syndrome of menopause, or GSM, caused by a roughly 95 percent drop in estrogen that thins and dries the tissue of the vagina, vulva, urethra, and bladder. GSM is usually described as a postmenopausal condition, but the estrogen decline behind it often starts in perimenopause, so symptoms can begin before periods stop completely.
About 75 percent of postmenopausal women experience vaginal dryness, 40 percent experience pain during intercourse, and 30 to 40 percent experience urinary urgency, frequency, or recurrent infections. Left untreated, GSM tends to get worse over time rather than better, and like every other menopause symptom, it deserves to be treated rather than quietly managed.
The stakes can be higher than discomfort. A 2026 analysis of nearly 1.9 million women in the Epic Cosmos database found that women prescribed vaginal estrogen after a recurrent urinary tract infection had significantly lower odds of sepsis, hospitalization, and death, with the strongest effect in the 40-to-54 and 55-to-69 age brackets. That age range spans perimenopause through post menopause, not postmenopausal women only, since the analysis grouped women by age rather than by confirmed menopausal status.
That alone is reason enough for every woman in the menopause transition to bring vaginal estrogen up with her doctor, whether she has symptoms yet or not.
What Vaginal Estrogen Is
Vaginal estrogen is a low-dose, local form of estrogen applied directly to the vaginal tissue rather than taken systemically. In Canada, it comes as a cream (Premarin, Estrace), a tablet inserted with an applicator (Vagifem and its generic, Yuvafem), or a ring that stays in place for about three months (Estring, Femring).
All three forms are similarly effective for treating GSM itself, though studies comparing them find women tend to rate the ring highest for convenience, since it requires no daily or weekly routine once inserted. Cream has one practical advantage the others do not: because it is applied by hand or with an applicator, it can also be spread a little onto the external vulvar tissue, which some women find helpful if dryness and irritation extend beyond the vagina itself.
The trade-off is that cream is messier and harder to dose precisely than a tablet or ring. There is no single best option; the right form usually comes down to which routine a woman will stick with long term.
This is a different approach from two other local options covered in our non-hormonal treatment post: ospemifene (Osphena), a pill that acts on estrogen receptors without being estrogen itself, and vaginal DHEA (Intrarosa), a hormone precursor that converts to small amounts of estrogen and androgen after insertion. Vaginal estrogen is the oldest option in this category by decades; ospemifene and vaginal DHEA were both approved much more recently.
Most of the research behind vaginal estrogen has nothing to do with UTIs. In randomized, placebo-controlled trials, vaginal estrogen cream reduced the severity of pain during sex and vaginal dryness within eight to twelve weeks compared with placebo.
The UTI protection covered below is not new evidence. A landmark 1993 randomized trial found the same vaginal estrogen cream cut UTI recurrences from nearly six episodes a year down to about one, but that finding sat underused in everyday practice for decades. What has changed recently is the scale of confirmation behind it, and the fact that professional guidelines are only now catching up.
Beyond Dryness: The UTI Prevention Benefit
Vaginal estrogen does more than treat dryness. The 2025 clinical practice guideline from the American Urological Association, the Society of Urodynamics, and the American Urogynecologic Society recommends that clinicians offer local low-dose vaginal estrogen specifically to reduce the risk of future urinary tract infections in postmenopausal women with GSM and a history of recurrent UTIs.
That is a direct recommendation from urology and gynecology’s own professional bodies, not a secondary or anecdotal benefit.
The life-saving stat mentioned above comes from this same 2026 Epic Cosmos analysis: women prescribed vaginal estrogen soon after a recurrent UTI diagnosis had lower odds of sepsis, hospital admission, and death, roughly 40 to 80 percent lower depending on the outcome and age group, with the most pronounced protection in the 40-to-54 and 55-to-69 age brackets. The difference was not statistically significant in women under 55.
The Safety Data Is More Reassuring Than the Reputation
Because vaginal estrogen is still estrogen, many women assume it carries the same risk profile as systemic hormone therapy. The data says otherwise.
Absorption into the bloodstream is minimal, and blood estrogen levels generally stay within the normal postmenopausal range even with the lowest-dose formulations. Large studies covering more than a thousand women on unopposed vaginal estrogen, meaning without added progesterone, have not found an increased risk of endometrial cancer, and research has not found an increased risk of blood clots, stroke, or heart disease either.
The U.S. FDA finalized removal of its boxed warning about breast cancer risk from vaginal estrogen products specifically in February 2026, acknowledging that their safety profile is distinct from systemic hormone therapy’s. Health Canada has not made the equivalent change yet, though Canadian medical organizations are working with Health Canada to update the labelling and guidance to reflect the same evidence.
This reassurance extends well beyond breast cancer. Because vaginal estrogen works locally rather than raising estrogen levels throughout the body, most cancer survivors, including many with endometrial, cervical, or ovarian cancer, are still considered safe candidates for it, even though those are exactly the cancers that rule out systemic estrogen.
A large study in endometrial cancer survivors found no meaningful difference in recurrence between those using vaginal estrogen and those who were not, and research in ovarian and cervical cancer survivors has found recurrence and other serious adverse events to be infrequent. For breast cancer survivors specifically, the American College of Obstetricians and Gynecologists supports vaginal estrogen for those whose symptoms do not respond to non-hormonal options, and it appears safe with hormone receptor-negative disease or with tamoxifen.
This is also worth raising with more than just yourself. If there is a mother, aunt, or older friend in your life who has never heard of vaginal estrogen, she is worth mentioning this to directly, even if she is well into her seventies or eighties and has been postmenopausal for decades.
Older women with recurrent UTIs remain part of the population that stands to benefit from this protection, and it is never too late to bring this up with her doctor.
Non-Hormonal Options at a Glance, for Comparison
| Vaginal Estrogen | Cream, tablet, or ring; low-dose and local; standard of care for GSM and UTI prevention; minimal systemic absorption. |
| Ospemifene (Osphena) | Oral pill that acts on estrogen receptors in vaginal tissue without functioning as hormone therapy elsewhere in the body. |
| Vaginal DHEA (Intrarosa) | Inserted directly; converts locally into small amounts of estrogen and androgen; Health Canada approved in 2019. |
| Moisturizers and Lubricants | First-line, over the counter, no prescription needed; often used alongside any of the above. |
Why This Matters at Work
GSM does not usually come up in a workplace conversation, but urinary urgency, discomfort, and recurrent infections affect concentration, comfort, and confidence during a normal workday just as much as hot flashes do.
An employee managing this quietly is not being dramatic or oversharing if she asks for flexibility around bathroom access or time for a medical appointment. Treatable does not stop being true just because a symptom is more private than a hot flash.
None of this is medical advice; talk to a doctor who knows your full health history before starting any hormone therapy, local or systemic, especially with a personal history of breast cancer.
Learn more about estrogen, progesterone, and testosterone, the three key hormones you need to understand.
I am not a doctor. Always talk to your own doctor before starting, stopping, or changing any medication.
—
Aimee Debow is the Founder of Menovate and a certified Menopause Coach. She appeared as a witness before the House of Commons Standing Committee on the Status of Women in June 2026. Menovate helps Canadian organizations build menopause-supportive workplaces through corporate talks, e-learning, and HR advisory services. Learn more at menovate.ca.